Astellas, Sanofi, Lundbeck up for innovation award; Lilly launches online molecule board game;

> Astellas' Dificlir, Sanofi's ($SNY) Lemtrada and Lundbeck's Selincro are a few of the contenders up for the 2014 Innovative Drug Award. Report

> IMS Health has announced it intends to acquire certain Cegedim information solutions and Customer Relationship Management businesses for €385 million ($520 million) in cash. Release

> Forest Laboratories' ($FRX) Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, three late-stage studies show. Report

> Alexion ($AXLN) and Cincinnati Children's Hospital Medical Center have announced the establishment of a collaboration and fund for the advancement of research in rare disease. Release

> A University of Tokyo investigation panel found 'serious faults' in a Novartis ($NVS) significant input of company employees in the trial's planning stages. More

And Finally... Eli Lilly's ($LLY) new online board game, "Destination Discovery," helps users experience the challenges of "bringing a new medicine from molecule to medicine cabinet." More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

Telehealth is surging during the pandemic, however, pharma companies’ place in the booming practice is still emerging.

Merck is expanding its cancer awareness effort with journalist Katie Couric to include survivorship and screening topics and a new podcast next month.